Company family · HQ ES
Almirall: medicine shortages
ALM · BME Madrid
As of 2 Nov 2026, 14 Almirall products have a reported shortage across 4 countries, covering 5 medicines.
Products short14rank #138 of 464
Medicines5active ingredients
Countries4/16
New in 90 days9-1 vs market pace
Typical duration52 daysmedian so far
Manufacturing15%demand-driven 62%
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Isotretinoin | 8 | 18 Jun 2026 | Increased demand | 4/16 | |
| Ispaghula (Psylla Seeds) | 1 | 19 Oct 2026 | Manufacturing problem | 2/16 | |
| Sulfamethoxazole and Trimethoprim | 1 | 22 Jul 2026 | Not stated | 5/16 | |
| Tacalcitol | 1 | 1 Oct 2026 | Manufacturing problem | 1/16 | |
| Tretinoin, Combinations | 1 | 1 Oct 2026 | Distribution or logistics | 1/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.